ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO

Zivo Bioscience, Inc.

Andrew A. Dahl terminated as President and CEO on January 4, 2022.
John B. Payne, previously Chairman, appointed President and CEO effective January 7, 2022.
Payne founded Compassion-First Pet Hospitals; served as President and CEO until 2020.
Payne removed from Compensation and Audit Committees; Christopher Maggiore appointed.
Company highlights 2021 progress including Nasdaq uplisting; expects seamless transition.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John B. Payne

President and Chief Executive Officer

ZIVO · Zivo Bioscience, Inc.

Effective: 2022-01-07
Filed: January 11, 2022, 6:59 PM ET

Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.

Departed

Andrew A. Dahl

President and Chief Executive Officer

ZIVO · Zivo Bioscience, Inc.

Effective: 2022-01-04
Successor: John B. Payne
Filed: January 11, 2022, 6:59 PM ET

On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John B. Payne was appointed as President and Chief Executive Officer at Zivo Bioscience, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.

View on SEC.gov

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-000342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.